These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 14624369

  • 1. Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen.
    Landay AL, Spritzler J, Kessler H, Mildvan D, Pu M, Fox L, O'Neil D, Schock B, Kuritzkes D, Lederman MM, AIDS Clinical Trials Group 5014 Team.
    J Infect Dis; 2003 Nov 15; 188(10):1444-54. PubMed ID: 14624369
    [Abstract] [Full Text] [Related]

  • 2. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.
    Antivir Ther; 2004 Apr 15; 9(2):197-204. PubMed ID: 15134181
    [Abstract] [Full Text] [Related]

  • 3. Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children.
    Borkowsky W, Stanley K, Douglas SD, Lee S, Wiznia A, Pelton S, Yogev R, McIntosh K, Nachman S.
    J Infect Dis; 2000 Jul 15; 182(1):96-103. PubMed ID: 10882586
    [Abstract] [Full Text] [Related]

  • 4. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
    Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D, ANRS 121 Hippocampe study group.
    AIDS; 2009 Apr 27; 23(7):817-24. PubMed ID: 19363330
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Nevirapine (Viramune): a new HIV inhibitor].
    De Wit S, Sternon J, Clumeck N.
    Rev Med Brux; 1999 Apr 27; 20(2):95-9. PubMed ID: 10335104
    [Abstract] [Full Text] [Related]

  • 10. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.
    AIDS; 2008 Jul 11; 22(11):1305-12. PubMed ID: 18580610
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG.
    Clin Infect Dis; 2005 Nov 01; 41(9):1326-32. PubMed ID: 16206110
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.